Cost-effectiveness and cost-utility evaluation of individual vs. group transdiagnostic psychological treatment for emotional disorders in primary care (PsicAP-Costs): a multicentre randomized controlled trial protocol

Abstract

Background Emotional disorders are common, and they have become more prevalent since the COVID-19 pandemic. Due to a high attendance burden at the specialized level, most emotional disorders in Spain are treated in primary care, where they are usually misdiagnosed and treated using psychotropic drugs. This contributes to perpetuate their illness and increase health care costs. Following the IAPT programme and the transdiagnostic approach, the PsicAP project developed a brief group transdiagnostic cognitive-behavioural therapy (tCBT) as a cost-effective alternative. However, it is not suitable for everyone; in some cases, one-on-one sessions may be more effective. The objective of the present study is to compare, in cost-benefit terms, group and individual tCBT with the treatment usually administered in Spanish primary care (TAU). Methods A randomized, controlled, multicentre, and single-blinded trial will be performed. Adults with mild to moderate emotional disorders will be recruited and placed in one of three arms: group tCBT, individual tCBT, or TAU. Medical data and outcomes regarding emotional symptoms, disability, quality of life, and emotion regulation biases will be collected at baseline, immediately after treatment, and 6 and 12 months later. The data will be used to calculate incremental cost-effectiveness and cost-utility ratios. Discussion This trial aims to contribute to clinical practice research. The involvement of psychologists in primary care and the implementation of a stepped-care model for mental disorders are recommended. Group therapy and a transdiagnostic approach may help optimize health system resources and unblock waiting lists so that people can spend less time experiencing mental health problems. Trial registration ClinicalTrials.gov: NCT04847310; Protocols.io: bx2npqde. (April 19, 2021)

Cost-Effectiveness of Group Transdiagnostic Cognitive Behavioural Therapy for Anxiety Disorders in Primary Care Settings: Economic Evaluation From the Healthcare System Perspective Over a 1-Year Time Horizon

“…To our knowledge, very few studies have assessed the cost-effectiveness of group tCBT. 29,31,56 In the current study, the ICER adjusting for potential baseline confounders was $6,581/QALY in the intention-to-treat analysis, which was similar to the ICER of $6,642/QALY observed in the complete case analysis. These estimates are similar to those reported on the effectiveness and cost-effectiveness of CBT for anxiety disorders.…”

Resilience, Stress, Well-Being, and Sleep Quality in Multiple Sclerosis

“…Because of the impact of resilience on psychological and physical health, and because it can be improved [ 78 ], resilience deserves greater attention in MS care. Support groups have proven especially effective at resilience-building [ 78 , 79 , 80 , 81 ], and they remain some of the most accessible and cost-efficient tools for mental health improvement [ 82 ].…”

Effectiveness of drama-based therapies on mental health outcomes: A systematic review and meta-analysis of controlled studies.

“…Because the studies included in our meta-analysis all followed a format for group interventions, it seems justified to suggest that healthcare providers should consider, as a matter of policy, whether drama-based therapies are offered in group or individual formats. This may help optimize the allocation of health system resources and unblock today's long waiting lists (Aguilera-Martín et al, 2022; Uttley et al, 2015).…”